The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis by Farshad Kajbaf & Jean-Daniel Lalau
Kajbaf and Lalau BMC Pharmacology and Toxicology 2013, 14:22
http://www.biomedcentral.com/2050-6511/14/22RESEARCH ARTICLE Open AccessThe prognostic value of blood pH and lactate
and metformin concentrations in severe
metformin-associated lactic acidosis
Farshad Kajbaf1 and Jean-Daniel Lalau1,2*Abstract
Aims: Analysis of the prognostic values of blood pH and lactate and plasma metformin concentrations in severe
metformin-associated lactic acidosis may help to resolve the following paradox: metformin provides impressive,
beneficial effects but is also associated with life-threatening adverse effects.
Research design and methods: On the basis of 869 pharmacovigilance reports on MALA with available data on
arterial pH and lactate concentration, plasma metformin concentration and outcome, we selected cases with a pH
< 7.0 and a lactate concentration >10 mmol/L. Outcomes were compared with those described for severe
metformin-independent lactic acidosis.
Results: Fifty-six patients met the above-mentioned criteria. The mean arterial pH and lactate values were 6.75 ± 0.17
and 23.07 ± 6.94 mmol/L, respectively. The survival rate was 53%, even with pH values as low as 6.5 and lactate
and metformin concentrations as high as 35.3 mmol/L and 160 mg/L (normal < 1 mg/L), respectively. Survivors and
non-survivors did not differ significantly in terms of the mean arterial pH and lactate concentration. The mean
metformin concentration was higher in patients who subsequently died but this difference was due to a very high
value (188 mg/L) in one patient in this group, in whom several triggering factors were combined. Sepsis, multidrug
overdoses and the presence of at least two triggering factors for lactic acidosis were observed significantly more
frequently in non-survivors (p = 0.007, 0.04, and 0.005, respectively). This contrasts with a study of metformin-
independent lactic acidosis in which there were no survivors, despite less severe acidosis on average (mean pH: 6.86).
Conclusions: In 56 cases of severe metformin-associated lactic acidosis, blood pH and lactate did not have prognostic
value. One can reasonably rule out the extent of metformin accumulation as a prognostic factor. Ultimately, the
determinants of metformin-associated lactic acidosis appear to be the nature and number of triggering factors.
Strikingly, most patients survived - despite a mean pH that is incompatible with a favorable outcome under other
circumstances.
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We have previously shown that neither blood lactate
concentration nor plasma metformin concentration was of
prognostic value with respect to mortality in so-called
metformin-associated lactic acidosis (MALA) [1,2]. How-
ever, given that arterial pH and blood lactate concentration
may vary (from ≤ 7.34 to 6.4 and from > 5 mmol/L to* Correspondence: lalau.jean-daniel@chu-amiens.fr
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distribution, and reproduction in any medium35.5 mmol/L, respectively, in our experience [2]), a
focus on severe MALA is needed in order to try to
better understand the paradox whereby metformin provides
impressive, beneficial effects but is also associated
with life-threatening adverse effects.Methods
Merck Serono provided us with access to its pharma-
covigilance database on metformin. We systematically
searched for and studied cases recorded as “metformin-tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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August 2010.
The database is a compilation of all cases worldwide
brought to Merck Serono’s attention during the study
period. Most entries are indirect, i.e. cases for which infor-
mation is transmitted to Merck Serono by local or national
health authorities. Other cases are documented through
spontaneous declarations (from physicians, pharmacists,
patients, etc.) or via the medical literature.
On the basis of these cases, the criteria for study selection
were the presence of severe lactic acidosis at admission
(defined as an arterial pH < 7.0 and a blood lactate concen-
tration >10 mmol/L) and the availability of data on the
plasma metformin concentration (regardless of the assay
used) and survival (defined as discharge from the intensive
care unit).
Comparisons between survivors and non-survivors
were made using Student’s unpaired t-test for quantitative,
demographic variables and a chi-2 test for qualitative
variables. Test results with p-values ≤0.05 were considered
to be statistically significant.
Outcomes were compared with those in Friesecke et al.
recent study [3], in which cases of severe MALA were com-
pared with cases of similarly severe metformin-independent
lactic acidosis.
The present study was approved by the local
investigational review board (Commission
d’Evaluation Ethique des Recherches Non
Interventionnelles, avis n° 101, Espace Ethique
Hospitalier Amiens Picardie, Amiens, France).
Results
Fifty-six patients (17 males and 39 females) met the
selection criteria (out of a series of 869 case reports
of MALA from 32 countries. Most cases (74.7%)
came from Europe.
The population’s main characteristics are summarized in
Table 1. The mean ± SD (range) age was 62.9 ± 12.1
(39–83) and the mean serum creatinine level was 587 ±
279 μmol/L (57–1000). The mean arterial pH was 6.75 ±
0.17 (6.28-6.99), the mean lactate concentration was
23.07 ± 6.94 mmol/L (10.9-55.7) and the mean plasma
metformin concentration was 50.64 ± 42.19 mg/LTable 1 Characteristics of the study population (mean ± SD) [
All patients (n = 56) Survivors (n =
Age 62.9 ± 12.1 [39–83] 61.7 ± 11.1 [40–
Creatinine, μmol/L 587 ± 270 [57–1000] 672 ± 265 [133–1
pH 6.75 ± 0.17 [6.28-6.99] 6.73 ± 0.17 [6.30-
Lactate, mmol/L 23.07 ± 6.94 [10.9-55.7] 22.24 ± 4.72 [14–
Plasma metformin level, mg/L 48.3 ± 39.6 [0.8-188] 39.66 ± 34.22 [0.8(0.8-188 mg/L). The latter value may well be the
highest ever reported.
Only 2 patients (3.5%) had a plasma metformin
concentration within the therapeutic range (based on
the upper limit of 2.5 mg/L recently proposed [4]). The
majority of patients (73%) displayed marked metformin
accumulation, with a value over 25 mg/L.
The overall survival rate in these patients was 53.6%
(30 out of 56). This rate did not depend on the date
during the study period (data not shown). In other
words, the outcome was not more favorable because of
more recent observations in survivors. Some patients
survived even with pH values as low as 6.5 and lactate
and metformin concentrations as high as 35.3 mmol/L
and 160 mg/L (N < 1 mg/L), respectively.
Survivors and non-survivors did not differ significantly
in terms of the mean arterial pH and lactate concentra-
tion. Individual patient data for these two parameters are
shown in Figure 1. The mean metformin concentration
was higher in non-survivors.
The main presumed triggering factors for lactic acidosis
are presented in Table 2 and are grouped into four
categories: kidney failure, other organ failures, overdose
and other conditions. Sepsis and multi-drug intoxication
rates were significantly higher in non-survivors than in
survivors (p = 0.007 and 0.04, respectively).
We also analyzed the number of presumed triggering
factors per patient as a function of the outcome (Table 3).
The presence of only one factor was more frequent in
survivors (p = 0.01) than in non-survivors; conversely,
the presence of two or more combined factors appeared
to be significantly more frequent in non-survivors than
survivors (p = 0.005).
A comparison of our study results with those of
Friesecke et al. [4] shows the same proportion of MALA
survivors (around 50%) and the same mean pH (pH 6.75
in both studies). In contrast, Friesecke et al. did not
report on any survivors in metformin-independent
lactic acidosis, despite the presence of less severe
acidosis (mean pH: 6.86).
Discussion
To the best of our knowledge, this is the largest series of
metformin-treated patients with severe lactic acidosis yetrange]
30) Non-survivors
(n = 26)
p-value for the survivor/non-survivor
comparison
81] 64.2 ± 13.1 [39–83] 0.44
000] 508 ± 310 [57–929] 0.09
6.98] 6.79 ± 0.17 [6.28-6.99] 0.16
35.3] 24.0 ± 8.9 [10.9-55.7] 0.26
-160] 63.3 ± 47.4 [1.01-188] 0.04
Figure 1 Arterial pH (a) and lactate concentrations (b) as a
function of the plasma metformin concentrations and outcome
in 56 patients with severe lactic acidosis (□. survivors; ■. non-
survivors).
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patients (53%) survived, despite a mean arterial pH of
6.73 and a mean lactate concentration of over 20 mmol/L
(22.24 mmol/L). In comparison, the mean arterial pH in
our previous series of unselected MALA patients was
much higher, at 7.04 (arterial lactate concentration:
15.1 mmol/L) [2].
Even though most of the patients survived (independ-
ently of age), it is important to know whether survival
was related to the severity of lactic acidosis, the extent
of metformin accumulation and/or the nature and num-
ber of triggering factors. A link with lactic acidosis per
se can be ruled out, since mean pH and lactate values
were similar in survivors and non-survivors. Even
though the mean metformin concentration was higher
in non-survivors, metformin responsibility can also be
ruled out with a good degree of confidence because this
concentration difference was due to a very high value
(188 mg/L, N < 1 mg/L) in only one non-survivor having
combined triggering factors.Indeed, outcomes appeared to be strongly correlated with
(i) the nature of the triggering factors, since some condi-
tions were significantly more frequent in non-survivors
(i.e. sepsis and multidrug intoxication, with p values
of 0.007 and 0.04, respectively) and (ii) the number
of triggering factors, since the presence of just one factor
was more frequent in survivors and two or more factors
were more frequently observed in non-survivors.
The fact that metformin concentrations may widely
vary in MALA complicates analysis of outcomes. Indeed,
metformin-treated patients do not necessarily develop
lactic acidosis - even in the presence of marked metfor-
min accumulation [5]. It is nevertheless possible to
distinguish patients according to their metformin level:
(i) undetectable or low, (ii) normal, (iii) slight to moder-
ate elevation or (iv) marked elevation [6]. In our previ-
ous report, we noted that 6 of the 49 patients (12.2%)
had a plasma metformin concentration at or below the
upper limit of the therapeutic range [2]. The homoge-
neous distribution of metformin concentrations in the
present series enabled us to better test for an associ-
ation between metformin accumulation and outcome.
Indeed, only 3.5% of the patients had a low value,
whereas the great majority (almost 80%) had marked
accumulation, >10 mg/L.
Lastly, we are keen to reconcile the impressively benefi-
cial metabolic and vascular effects of metformin on one
hand with the drug’s widely assumed, potentially lethal
toxicity in MALA on the other – as summed up by a
sentence like “metformin-associated lactic acidosis is rare
but is still associated with a high mortality rate”.
Indeed, our report on a rather large series of patients
with severe MALA and a death rate of almost 50% high-
lights how severe the complication really is. However,
the problem is much more complex than that, since
MALA is not a clearly defined clinical entity [7]. One
way to circumvent this difficulty is thus to compare the
outcome in MALA with that in metformin-independent
lactic acidosis. The data from Friesecke et al. recent
study (in which MALA was compared with similarly
severe lactic acidosis due to other causes) showed the
same proportion of survivors (around 50%) and the same
mean pH (6.75) for MALA as in our (much larger) series
but, strikingly, did not feature any survivors in
metformin-independent lactic acidosis (despite less
severe acidosis (mean pH: 6.86)) [4]. There are two
possible explanations for this striking difference in survival
when comparing MALA and metformin-independent
lactic acidosis: (i) the presence of less severe, acidosis-
triggering co-morbidities in MALA patients (because
metformin accumulation is responsible for a proportion of
cases of observed acidosis) and/or (ii) a protective effect of
metformin (due to its vascular properties [8] and its action
on the respiratory-chain complex [9]).
Table 2 Prognosis according to the presumed main triggering medical conditions (one condition per patient or more)
Associated condition Total n Survivors n (%) Non-survivors n (%) p-value for survivor/ non-survivor comparison
Kidney failure
Total 34 19 (55.9) 15 (44.1) 0.87
Acute failure 21 11 10 0.89
Chronic failure 7 5 2 0.43
Duration unspecified 6 3 3 1.00
Other organ failures
Total 10 6 4 0.74
Liver 4 2 2 1.00
Cardiovascular system 3 3 0 0.24
Lung 3 1 2 0.59
Overdose
Total 8 3 5 0.45
Metformin (alone) 4 3 1 0.61
Multidrug (including metformin) 4 0 4 0.04
Other conditions
Total 13 3 10 0.02
Sepsis 6 0 6 0.007
Alcohol abuse 3 2 1 1.00
Cancer 1 0 1 0.46
Pancreatitis 1 1 0 1.00
Neurological disorder 1 0 1 0.46
Acute denutrition 1 0 1 0.46
Indetermined 3 2 1 1.00
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most remarkable finding is the unexpectedly high propor-
tion of MALA survivors - despite an arterial pH as low as
6.5 (in 5 patients) and a lactate concentration as high as
35.3 mmol/L. However, this observation is coherent with
the growing body of preclinical and clinical evidence
demonstrating unexpectedly rapid recovery and survival in
massive metformin accumulation and/or very severe
MALA [8-13].
Conclusions
In comparison with common forms of lactic acidosis, se-
vere MALA is particular in that the majority of patients
survive – despite a mean pH that is usually thought to
be fatal. For this type of MALA patients, the outcome
was related to the nature and number of triggeringTable 3 Prognosis according to the number of presumed trig
Number of medical conditions Total n Survivors n (
No identified conditions or scarce information 3 2
1 38 25 (65.8)
2 or more 15 3 (20)factors, rather than the severity of lactic acidosis or the
extent of metformin accumulation.
Key messages
 Analysis of the outcomes in severe metformin-
associated lactic acidosis may help to resolve the
following paradox: metformin provides beneficial
effects but is also associated with life-threatening
adverse effects.
 In 56 cases of severe metformin-associated lactic
acidosis (pH < 7.0 and a lactate concentration
>10 mmol/L), blood pH and lactate did not have
prognostic value.
 The extent of metformin accumulation cannot not
be considered as a prognostic factor.gering medical conditions
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acidosis appeared to be the nature and number of
triggering factors.
 Most patients survived despite a mean pH that is
incompatible with favorable outcomes under other
circumstances. Such an unexpectedly favorable
outcome prompted to form a challenging hypothesis
whereby metformin may be protective in severe
lactic acidosis that occurs for other reasons in
patients taking this drug.
Abbreviation
MALA: Metformin-associated lactic acidosis.
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